Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 16.5 -0.76 (-4.4%) Market Cap: 304.04 Mil Enterprise Value: 303.15 Mil PE Ratio: 75.04 PB Ratio: 0 GF Score: 77/100

Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 03:30PM GMT
Release Date Price: $23.9 (-6.64%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, I'm one the senior biotech analysts here at JPMorgan. I'm pleased to welcome our next presenting company, Rigel Pharmaceuticals. And presenting on behalf of the company, we have CEO, Raul Rodriguez. Before I'd -- I'd like to hand it over to Raul to start his presentation.

Raul R. Rodriguez
Rigel Pharmaceuticals, Inc. - President, CEO & Director

Thank you, Tessa. I appreciate it, and thank you, everyone, for attending the conference. It's nice to be able to present to you this day. First, let me start with an important forward-looking statement that pertains to this presentation. You can review this statement on our website as well as our filings at the SEC.

Let me start on Slide 3. In 2021, we made important progress across all the key value drivers for Rigel, that you see here on this slide. And what this does, is set us up with what we believe will be a transformative year for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot